Hayley Virgil is a senior editor with CancerNetwork. When she isn't traveling to conferences and championing health equity in the oncology space, she can be found hiking, foraging wild plants, gardening, sewing ballgowns, practicing embroidery, or playing video games.
Ripretinib Receives FDA BTD for KIT+ Gastrointestinal Stromal TumorsMarch 16th 2023
National Comprehensive Cancer Network guidelines will now include ripretinib as the ideal second-line treatment for patients with unresectable/metastatic gastrointestinal stromal tumors who are intolerant to sunitinib.
Pembrolizumab/Chemo Appears to Improve Survival in Advanced MesotheliomaMarch 13th 2023
The final analysis of the phase 2/3 CCTG IND.227/KEYNOTE-483 trial identifies a statistically significant survival benefit with pembrolizumab and chemotherapy vs chemotherapy alone in the first-line setting for patients with unresectable advanced or metastatic malignant pleural mesothelioma.
FDA Expands Abemaciclib Approval to Include HR+ HER2– Node+ High-Risk Breast CancerMarch 3rd 2023
Patients with hormone receptor–positive, HER2-negative, node-positive early breast cancer at a high risk of relapse who are eligible for treatment with abemaciclib can be identified via nodal status as well as tumor size and grade.
FDA Receives NDA for Niraparib/DAT Abiraterone in Prostate Cancer SubtypeMarch 1st 2023
Patients with BRCA-positive metastatic castration-resistant prostate cancer may benefit from treatment with niraparib plus dual action abiraterone acetate tablets and prednisone, a new drug application for which was submitted to the FDA.
NCCN Guidelines Update Includes Injection for Cisplatin Ototoxicity in AYAsFebruary 14th 2023
A medical oncologist and research audiologist from St. Jude Children’s Research Hospital discuss how sodium thiosulfate injection may improve quality of life by preventing cisplatin-associated ototoxicities in pediatric patients with localized non-metastatic tumors, although more research is needed.
ODAC Votes 8-5 in Favor of Dostarlimab Trial in Advanced Rectal CancerFebruary 9th 2023
In a meeting with the FDA’s Oncologic Drugs Advisory Committee experts discussed findings that have read out with regard to dostarlimab for patients with mismatch repair deficiency/microsatellite instability–high locally advanced rectal cancer.
Meeting Needs, Dismantling Barriers to Cancer Care: A Patient Advocate Weighs inFebruary 3rd 2023
“Being a patient advocate means not so much putting ourselves in the patient's shoes but asking the right questions to find out what those barriers to care are,” says an oncology survivorship navigator from Sibley Memorial Hospital, Johns Hopkins Medicine.
KIT Mutational Status Correlates With Response in Advanced GISTJanuary 25th 2023
An expert from the Smilow Cancer Hospital and Yale Cancer Center indicates that findings from the ctDNA analysis of the phase 3 INTRIGUE study were “provocative” and that the subsequent phase 3 INSIGHT study has the potential to be practice changing should data be positive.
ctDNA May Be Ideal Biomarker for Early Response Assessment in Advanced Colorectal CancerJanuary 22nd 2023
Molecular responders by G360 response algorithm with advanced colorectal cancer appear to have significantly lengthened time on treatment and overall survival with all regimens vs patients who did not respond.
FDA Gives Investigational Drug Fast Track Designation for Advanced Breast Cancer SubtypeJanuary 13th 2023
The investigational drug CFI-402257 alone and in combination with fulvestrant received fast track designation from the FDA for patients with estrogen receptor–positive, HER2-negative advanced breast cancer.
Statistically Significant, Clinically Meaningful OS Improvement Observed With TTFields for Stage IV NSCLCJanuary 9th 2023
The overall survival improvements were observed when tumor-treating fields were combined with immune checkpoint inhibitors with a positive trend towards improvement when combined with docetaxel in those with stage IV non–small cell lung cancer.
FDA Approves Liquid Biopsy Test as a Companion Diagnostic for Entrectinib in Lung Cancer Patient SubgroupJanuary 5th 2023
The FDA’s decision means that oncologists can use FoundationOne Liquid CDx to identify patients with ROS1-positive non–small cell lung cancer or NTRK fusion–positive solid tumors who are eligible for treatment with entrectinib.
Durvalumab/Tremelimumab Approved in Japan for Advanced NSCLC and Select Unresectable GI CancersJanuary 4th 2023
The decision to approve durvalumab plus tremelimumab in Japan for patients with advanced non–small cell lung cancer and unresectable biliary tract cancer and liver cancer was based on data from several phase 3 studies.